If you have the patience, you can achieve innovation milestones, says Wockhardt chairman Habil Khorakiwala

Wockhardt Hospitals is set to launch its antibiotic Zaynich in the US. Zahabiya Khorakiwala will lead US operations. The drug is expected to generate $1.5-2 billion in peak annual sales within 4-6 years. Wockhardt aims for a 20% share of the AMR market. The company is also developing new antibiotics for its pipeline.